{"id":53713,"date":"2023-02-07T23:02:49","date_gmt":"2023-02-07T22:02:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/"},"modified":"2023-02-07T23:02:49","modified_gmt":"2023-02-07T22:02:49","slug":"sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/","title":{"rendered":"Sarissa Capital Highlights Amarin\u2019s Inaccurate and Misleading Statements"},"content":{"rendered":"
\n

\nSarissa urges all shareholders to vote the BLUE<\/b> proxy card for needed change at Amarin <\/i>on or prior to February 21, 2023<\/i>\n<\/p>\n

\nDo NOT<\/b> vote Amarin\u2019s WHITE proxy card<\/i>\n<\/p>\n

GREENWICH, Conn.–(BUSINESS WIRE)–Sarissa Capital Management LP (\u201cSarissa\u201d) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN):\n<\/p>\n

\nSarissa today released a presentation highlighting many of the inaccurate and misleading statements Amarin made in its attempts to thwart shareholder representation and oversight on the board. For Sarissa\u2019s presentation, please click on the link below.\n<\/p>\n

\nPresentation:<\/b> https:\/\/freeamarin.com\/wp-content\/pdfs\/presentation-slides-020723.pdf<\/a>\n<\/p>\n

\nVisit our website at www.freeamarin.com<\/a> for helpful information about Sarissa and the need for change at Amarin.\n<\/p>\n

\nVote the BLUE<\/b> proxy card \u201cFOR<\/b>\u201d the Sarissa Nominees and \u201cFOR<\/b>\u201d the removal of Chairman Per Wold-Olsen from the board.\n<\/p>\n

\nThe General Meeting of Amarin shareholders is scheduled for February 28, 2023, BUT TO MAKE SURE YOUR VOTE COUNTS, SUBMIT YOUR VOTE ON OR BEFORE TUESDAY, FEBRUARY 21, 2023<\/span><\/b>.\n<\/p>\n

\nShareholders should be receiving the BLUE<\/b> proxy card this week. If you do not receive your BLUE<\/b> proxy card this week or have any questions on how to vote, please contact:\n<\/p>\n

\nD.F. King & Co., Inc.
\n
48 Wall Street
\n
New York, New York 10005
\n
Shareholders call toll-free:<\/b> (800) 331-7024
\n
Banks and Brokers call:<\/b> (212) 269-5550
\n
By Email:<\/b> AMRN@dfking.com<\/a>\n<\/p>\n

\n#FreeAmarin\n<\/p>\n

\nAdditional Information<\/b>\n<\/p>\n

\nSarissa Capital Management LP (\u201cSarissa Capital\u201d), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc (the \u201cCompany\u201d) at the general meeting of the Company for the election of Sarissa Capital\u2019s slate of highly-qualified nominees (the \u201cGeneral Meeting\u201d). Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.\n<\/p>\n

\nThe definitive proxy statement and other relevant documents are available at no charge on the SEC\u2019s website at www.sec.gov<\/a> and at www.freeamarin.com<\/a>. The definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital\u2019s proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJean Puong
\n
Sarissa Capital Management LP
\n
info@sarissacap.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Sarissa urges all shareholders to vote the BLUE proxy card for needed change at Amarin on or prior to February 21, 2023 Do NOT vote Amarin\u2019s WHITE proxy card GREENWICH, Conn.–(BUSINESS WIRE)–Sarissa Capital Management LP (\u201cSarissa\u201d) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN): Sarissa today released a presentation highlighting many of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53713","6":"format-standard","7":"category-industry"},"yoast_head":"\nSarissa Capital Highlights Amarin\u2019s Inaccurate and Misleading Statements - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarissa Capital Highlights Amarin\u2019s Inaccurate and Misleading Statements - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Sarissa urges all shareholders to vote the BLUE proxy card for needed change at Amarin on or prior to February 21, 2023 Do NOT vote Amarin\u2019s WHITE proxy card GREENWICH, Conn.–(BUSINESS WIRE)–Sarissa Capital Management LP (\u201cSarissa\u201d) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN): Sarissa today released a presentation highlighting many of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-07T22:02:49+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Sarissa Capital Highlights Amarin\u2019s Inaccurate and Misleading Statements\",\"datePublished\":\"2023-02-07T22:02:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\\\/\"},\"wordCount\":388,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\\\/\",\"name\":\"Sarissa Capital Highlights Amarin\u2019s Inaccurate and Misleading Statements - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-02-07T22:02:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sarissa Capital Highlights Amarin\u2019s Inaccurate and Misleading Statements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sarissa Capital Highlights Amarin\u2019s Inaccurate and Misleading Statements - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/","og_locale":"en_US","og_type":"article","og_title":"Sarissa Capital Highlights Amarin\u2019s Inaccurate and Misleading Statements - Pharma Trend","og_description":"Sarissa urges all shareholders to vote the BLUE proxy card for needed change at Amarin on or prior to February 21, 2023 Do NOT vote Amarin\u2019s WHITE proxy card GREENWICH, Conn.–(BUSINESS WIRE)–Sarissa Capital Management LP (\u201cSarissa\u201d) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN): Sarissa today released a presentation highlighting many of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-07T22:02:49+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Sarissa Capital Highlights Amarin\u2019s Inaccurate and Misleading Statements","datePublished":"2023-02-07T22:02:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/"},"wordCount":388,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/","url":"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/","name":"Sarissa Capital Highlights Amarin\u2019s Inaccurate and Misleading Statements - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-02-07T22:02:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-highlights-amarins-inaccurate-and-misleading-statements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Sarissa Capital Highlights Amarin\u2019s Inaccurate and Misleading Statements"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53713"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53713\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}